News for Adial Pharmaceuticals, Inc. (ADIL)

GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( ADIL) (”œAdial” or the ”œCompany”), a clinical-stage biopharmaceutical

**media[556929]**

FDA feedback confirms Adial's proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory re

New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence GLEN AL

**media[482153]**

Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Adial Pharmaceuticals reports Q3 2024 net loss of $2.2 million, with cash and cash equivalents at $5.2 million as of September 30, 2024.

Michael Useem explains what effective leaders do well.

The company has repeatedly violated accounting principles.

Adial Pharmaceuticals appoints Vinay Shah as CFO, previously at Virpax Pharmaceuticals.

Adial Pharmaceuticals patent expands for alcohol disorder drug

**media[439663]**

Topline results expected in fourth quarter of 2024...

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Shares of NextPlat Corp (NASDAQ: NXPL) rose sharply in today’s pre-market trading after the company reported consolidated 2023 revenues of $37.8 million, up 222% year over year

Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.

U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 1% on Wednesday. The Dow traded down 1.15% to 38,438.09 while the NASDAQ fell 0.89% to 16,162.29. The S&P 500 also fell, dropping, 0.95% to 5,160.20.

Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6 million public offering of shares at $0.14 per share.

Pennsylvania-based healthcare business Societal CDMO, Inc. (SCTL) is up over 132% in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.